ramucirumab,pembrolizumab
eli lilly,merck
['s1800a', 'lung', 'ramucirumab', 'pembrolizumab']
patients whose advanced non-small cell #lungcancer progressed on prior #immunotherapy lived significantly longer when treated w combo ramucirumab + pembrolizumab vs standard of care. median os: 14.5 vs 11.6 mos. study s1800a at #asco22 
A lung cancer precision medicine trial and unique partnership of @theNCI @CancerResrch @FNIH_org and @SWOG Testing new treatments, including immunotherapies.